News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Toru Mukohara

Articles by Toru Mukohara

104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapy

ByKevin Kalinsky, MD, MS,Rachel M. Layman,Antonio Giordano,Toru Mukohara,Yeon Hee Park,Geoffrey J. Lindeman,Giampaolo Bianchini,Alexandre de Nonneville,Véronique Diéras, MD,Sherko Kuemmel,Shusen Wang,Zhiming Shao,Sean Kent,Griffith M. Davis,Meng Li,Mafalda Oliveira

May 19th 2026

8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

ByAditya Bardia, MD, MPH, FASCO,Ian E. Krop,Funda Meric-Bernstam, MD,Anthony W. Tolcher,Toru Mukohara,Aaron Lisberg,Toshio Shimizu,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Takahiro Kogawa

April 28th 2023

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

ByAditya Bardia, MD, MPH, FASCO,Ian E. Krop,Dejan Juric,Takahiro Kogawa,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Toru Mukohara,Takuya Tsunoda,Senthil Damodaran,Funda Meric-Bernstam, MD

April 28th 2023

Latest Updated Articles

Trending on CancerNetwork

Daraxonrasib/Vopimetostat Yield Stunning Response Rate in MTAP-del Pancreatic Cancer

Melanoma Trials You May Have Missed at ASCO 2026

80 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Final Results From the Phase 1b/2 BEGONIA Study

Subcutaneous Isatuximab Earns EU Approval in Multiple Myeloma

Radiation Oncology Trials You May Have Missed at ASCO 2026